Navigation Links
Nutrastar Announces Adoption of Share Repurchase Program

HARBIN, China, Aug. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced that its Board of Directors has authorized a share repurchase program under which Nutrastar may repurchase up to US$5 million of the Company's common stock over a period of 12 months.

Under the program, the Company may, from time to time make one or more purchases, through open market, block trades or in privately negotiated transactions in accordance with the applicable federal securities laws and regulations, including Rule 10b-18. The timing and extent of the repurchases will be determined by the Company's management, in its discretion, and will depend upon market conditions, the trading prices and volume of the stock, alternative uses for capital, the Company's financial performance, and other factors. The repurchase program does not obligate Nutrastar to make any repurchases at any specific time.  

Ms. Lianyun Han, CEO and founder of Nutrastar, commented, "Despite difficult macroeconomic conditions and volatility in the capital markets, we are confident in our business, our growth strategies and in the opportunities that lie ahead for our company. We stand by the legitimacy and validity of our cash position, financial results and internal controls that are reviewed and audited by our top-10 accounting firm. Our shareholders are vitally important to us and the adoption of this share repurchase program reflects our strong commitment to enhancing shareholder value as well as the confidence our Board of Directors and management team have in our ability to continue carrying out our growth strategy of expanding our product lines and distribution networks while also adding value to our shareholders in the long-term."

The program will be funded utilizing the Company's cash on hand and cash generated from operations. The Company is currently working with financial institutions to secure efficient and adequate conversion of Chinese Renminbi to U.S. Dollars to fund the execution of the repurchase program. The Board of Directors of the Company will periodically review the share repurchase program and may authorize adjustments to the program's terms and size. The Board of Directors may also suspend or discontinue the repurchase program at any time.  

About Nutrastar International Inc.Nutrastar is a China based leading producer and supplier of premium branded TCM consumer products including commercially cultivated Cordyceps Militaris and functional health beverages. Cordyceps Militaris is one of the most highly regarded herbal nutrients in TCM. The Company believes it is the largest manufacturer of bioengineered Cordyceps Militaris in China, ranked by volume, according to China Market Monitoring Center (CMMC), accounting for approximately 19% market share in China. The Company is headquartered in Harbin, capital of Heilongjiang province, with 321 employees, 21 in R&D, and 140 in sales and marketing. The products of Nutrastar are sold throughout China via a direct and distribution network that covers more than 10 provinces. More information may be found at or e-mail:

Make sure you are first to receive timely up-to-date information on Nutrastar. Sign up for Nutrastar's email news alert system today at:

Safe Harbor StatementThis news release contains "forward-looking statements" relating to the business of Nutrastar International Inc., its subsidiaries and other affiliate companies. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, the Company does not assume a duty to update any forward-looking statements to reflect events or circumstances after the date hereof.For more information, please contact:Robert Tick, CFONutrastar International Inc.Email: Howard GostfrandAmerican Capital VenturesTel:  +1-305-918-7000Email:

SOURCE Nutrastar International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
2. Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011
3. Nutrastar Distribution Spreads into Anhui Province
4. Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details
5. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
6. Nutrastar to Present at the Upcoming 2011 Global Hunter Securities Conference
7. Nutrastar Announces Second Quarter 2011 Financial Results
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 ... --> adds a 2015 ... 2010 - 2015 with comprehensive analysis ... range of deal types, such as ... alliances. . ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith has ... Healthcare, a global pioneer in wireless monitoring of ... Boston, MA , Mr. Smith will be ... global commercial strategy.  He will also directly oversee ... build clinical evidence for SensiumVitals, the first early ...
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
(Date:11/30/2015)... ... 01, 2015 , ... The National Association of Professional ... its VIP Woman of the Year Circle. She is recognized with this prestigious ... for professional women, boasting 850,000 members and over 200 operating Local Chapters. , ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... Jones as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. Louis Fetal ... MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI ... of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight and above ...
Breaking Medicine News(10 mins):